Recently completed a validation study on the presence of autoantibodies in plasma in two Swedish ME/CFS cohorts. We observed a significant up-regulation of autoantibodies in up to 70% of the patients. No autoantibodies could be found in cerebrospinal fluid (CSF), which is very good news, as that would make removal of the antibodies very difficult.
Preliminary studies using immunoadsorption and/or plasmapheresis to remove the antibodies show positive effects in at least a subpopulation of ME/CFS patients.
STUDY HYPOTHESIS AND DESCRIPTION
Previously, autoantibodies have been observed to have increased binding to adrenergic and muscarinic receptors in Myalgic Encephalomyelitis/ Chronic fatigue syndrome (ME / CFS) patients. It is hypothesized that these autoantibodies may be part of the pathogenesis of ME / CFS and patient symptom.
STUDY DESIGN
Plasma, CSF and health-related questionnaires were collected from two Swedish ME / CFS cohorts, plasma and CSF from one of the cohorts (n=24), only plasma from the second cohort (n=24) together with plasma samples (n=24) and CSF (n=6) from healthy controls.
All samples were analyzed for IgG autoantibodies directed against adrenergic and muscarinic receptors ELISA technique. The questionnaires were used as measures of disease severity.
This study has been published in Brain, Behavior and Immunity – Health
Open Medicine Foundation®
29302 Laro Drive, Agoura Hills, CA 91301 USA
Phone: 650-242-8669
Stay Informed
Be the first to hear our research news.
Subscribe Now.
Averting a second pandemic:
Open Medicine Foundation leads groundbreaking international study of
Long COVID’s conversion to ME/CFS
AGOURA HILLS, CALIF. — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome — to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.
Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”
OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.
The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.
BACKGROUND
In a significant percentage of patients, infections preceded their development of ME/CFS. For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.
THE STUDY
The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS. Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.
###
About Open Medicine Foundation
Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.
CONTACT:
Heather Ah San
Development and Communications Manager
1-650-242-8669